Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 6.

Vom Berg, Johannes; Buch, Thorsten (2018). Genänderung als Treiber der immunologischen Forschung. Von Spontanen Mutanten zu CRISPR/Cas9. Trillium Immunologie, 2(2):94-99.

Vom Berg, Johannes; Kobold, Sebastian (2017). The need for speed: how PD1-blockade only works if T cells are properly activated. Translational Cancer Research, 6(S6):S1018-S1021.

Bürgi, Sandra; Seuwen, Aline; Keist, Ruth; Vom Berg, Johannes; Grandjean, Joanes; Rudin, Markus (2014). In vivo imaging of hypoxia-inducible factor regulation in a subcutaneous and orthotopic GL261 glioma tumor model using a reporter gene assay. Molecular Imaging, 13(0):1-11.

Vom Berg, Johannes; Vrohlings, Melissa; Haller, Sergio; Haimovici, Aladin; Kulig, Paulina; Sledzinska, Anna; Weller, Michael; Becher, Burkhard (2013). Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. Journal of Experimental Medicine, 210(13):2803-2811.

Vom Berg, Johannes; Prokop, Stefan; Miller, Kelly R; Obst, Juliane; Kälin, Roland E; Lopategui-Cabezas, Ileana; Wegner, Anja; Mair, Florian; Schipke, Carola G; Peters, Oliver; Winter, York; Becher, Burkhard; Heppner, Frank L (2012). Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nature Medicine, 18(12):1812-1819.

Vom Berg, Johannes. Interleukin-12 in Combination with CTLA-4 Blockade Leads to T-cell Dependent Rejection of Advanced Stage Glioma. 2012, University of Zurich, Faculty of Medicine.

This list was generated on Thu Jun 27 07:07:35 2019 CEST.